Salute e Benessere

Revolutionizing Genetic Disease Research: DLI's Vital Role in Meeting Unmet…

DiseaseLandscape Insights with its healthcare consulting abilities has been supporting medical researchers and pharma organizations in their R&D activities. It has been helping various pharma firms in solidifying their position in the genetic disease market by providing them with drug launch strategies, post launch services, commercial strategy analysis, and product pipeline analysis-based pharma consulting services. DiseaseLandscape Insights with its healthcare consulting abilities has…
PR Newswire
26/09/2023

Regenerative Medicine Market Size to Hit USD 44.63 Billion by 2024, with at a…

Regenerative medicine stands at the forefront of medical innovation, offering the promise of restoring, replacing, and rejuvenating damaged tissues and organs. This burgeoning field holds immense potential to revolutionize healthcare, providing hope to patients with previously untreatable conditions. In this article, we dive into the current state of the regenerative medicine market, examining its size, market share, key trends, challenges, opportunities, threats, recent industry developments…
PR Newswire
26/09/2023

Biomarkers Market Is Projected to Witness A Robust Growth At A CAGR Of 14.1%…

In today's ever-evolving landscape of healthcare and diagnostics, biomarkers have emerged as a pivotal tool. These molecular indicators offer valuable insights into the physiological and pathological processes within the human body. The global biomarkers market has witnessed significant growth over the years, driven by a multitude of factors. In this article, we delve into the scope, segmentation, and market dynamics of the biomarkers market, providing a comprehensive overview of this burgeoning…
PR Newswire
26/09/2023

Empowering Pharmaceutical Companies in Chronic Disease Research and Identifying…

Disease Landscape Insights has been offering healthcare consulting services to these players with an aim to enhance their understanding on chronic disorders. It boasts a comprehensive portfolio of chronic disease research documents, encompassing a wide spectrum of ailments such as anemia, diabetes, stroke, obesity, arthritis, heart diseases, and more. Within DLI's extensive repository, these documents serve as a valuable resource, providing deep dive insights into the complexities of chronic…
PR Newswire
26/09/2023

Active Pharmaceutical Ingredients (API) Market Expected to Reach USD 284.4…

The global pharmaceutical industry plays a vital role in healthcare, and at the core of this industry are Active Pharmaceutical Ingredients (APIs). These essential components form the foundation of various pharmaceutical products, from common pain relievers to cutting-edge biotechnological drugs. In this comprehensive guide, we will delve into the Active Pharmaceutical Ingredients (API) market, examining its segmentation, major trends, drivers, opportunities, threats, target demographics, and…
PR Newswire
26/09/2023

Wearable Medical Devices Market to Earn Massive Revenue by 2028 | Brandessence…

In the era of rapidly advancing technology, wearable medical devices are taking center stage in revolutionizing healthcare. These innovative gadgets, ranging from activity monitors and smart clothing to patches and smartwatches, have the potential to enhance our understanding of health and well-being. This article delves into the Wearable Medical Devices Market, exploring product types, applications, industry analysis, and key trends that will shape the market from 2022 to 2028. In the era of...
PR Newswire
26/09/2023

Kanazawa University research: Researchers identify the dynamic behavior of a key…

"Similar to other viruses, SARS-CoV-2 expresses an array of accessory proteins to re-program the host environment to favor its replication and survival," explain Richard Wong at Kanazawa University and Noritaka Nishida at Chiba University and their colleagues in this latest report. Among those accessory proteins is ORF6. Previous studies have suggested that ORF6 potently interferes with the function of interferon 1 (IFN-I), a particular type of small protein used in the immune system…
PR Newswire
26/09/2023

Bioinformatics Market Size is Projected to Hit 24.07 Bn by 2028, With at a 12.1%…

Bioinformatics, a multidisciplinary field that combines biology, computer science, and information technology, has emerged as a pivotal player in the life sciences industry. It encompasses the storage, analysis, and interpretation of biological data, enabling scientists to extract valuable insights and accelerate advancements in genomics, proteomics, and other branches of life sciences. In this article, we delve into the current state of the bioinformatics market, exploring its size, market…
PR Newswire
26/09/2023

Vaccines Market Size To Reach USD 153.49 Billion, With at a 14.1% CAGR between…

In a world that has been irrevocably altered by the COVID-19 pandemic, the vaccines market has come into sharper focus than ever before. With the race to develop effective vaccines against the virus, the industry has witnessed unprecedented growth and innovation. However, the vaccines industry is not limited to just one virus; it encompasses a wide range of vaccines designed to combat various diseases. In this article, we will delve into the market, exploring its scope, segmentation, market…
PR Newswire
26/09/2023

Invitation to presentation of Essity's Interim Report for the third quarter 2023

CONTACT: CONTACT: For further information, please contact: Per Lorentz, Vice President Corporate Communications, +46 73 313 30 55,per.lorentz@essity.com Sandra Åberg, Vice President Investor Relations, +46 70 564 96 89,sandra.aberg@essity.com The following files are available for download: View original content: https://www.prnewswire.co.uk/news-releases/invitation-to-presentation-of-essitys-interim-report-for-the-third-quarter-2023-301938438.html
PR Newswire
26/09/2023

Beactica Therapeutics announces collaboration with the National Center for…

Pharmacological modulation of the Hippo signalling pathway has translational potential in both regenerative and oncology indications. Small-molecule modulators of the TEAD transcription factors have recently emerged as a novel anti-cancer drug-class, to specifically target Hippo-pathway-deficient cancers. Pharmacological modulation of the Hippo signalling pathway has translational potential in both regenerative and oncology indications. Small-molecule modulators of the TEAD transcription...
PR Newswire
26/09/2023

Acesion Pharma Closes Oversubscribed €45M Series B Financing Round to Advance…

The financing will be used to advance the clinical development of AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of AF. Earlier this year, Acesion demonstrated clinical proof-of-concept with AP30663, its first-in-class SK ion channel inhibitor for conversion of AF to normal sinus rhythm. The financing will be used to advance the clinical development of AP31969, an SK ion channel inhibitor optimised for chronic oral treatment of AF. Earlier this year, Acesion...
PR Newswire
26/09/2023

Nexstim Receives Order for NBS 5 System with NexSpeech®

Press release, Helsinki, 26 September 2023 at 9 AM (EEST)Nexstim Receives Order for NBS 5 System with NexSpeech® Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces having received an order for an NBS 5 system. The European end customer is new to Nexstim.Nexstim's NBS (Navigated Brain Stimulation) System 5, in this case with the addition of the NexSpeech® module, is indicated for the non-invasive, presurgical mapping of motor and speech cortices of the...
Nasdaq GlobeNewswire
26/09/2023

SONGMICS HOME Makes Debut with Pop-Up Showroom at Paris Design Week 2023

During the design week, SONGMICS HOME hosted a grand opening ceremony that attracted local French media outlets, industry celebrities, and partners. Franck Millot, the director of Paris Design Week, delivered a special address and highly appreciated the company's product creativity and cultural concept. SONGMICS HOME's CEO Robert Song and Product VP Peter Lee also participated the ceremony and offered some insightful views to audiences. During the design week, SONGMICS HOME hosted a grand...
PR Newswire
26/09/2023

Press Release: Dupixent® (dupilumab) sBLA for treatment of eosinophilic…

Dupixent ®(dupilumab) sBLAfor treatment of eosinophilic esophagitis in children aged 1 to 11 accepted for FDA Priority Review If approved, Dupixent would be the first and onlytreatment indicated in the U.S. for children aged 1- 11with eosinophilic esophagitis, a disease driven by type 2 inflammation that impacts the ability to eatOf the approximately 21,000 children under the age of 12 in the U.S. currently being treated for ...
Nasdaq GlobeNewswire
26/09/2023

Sandoz receives European Commission approval for Tyruko® (natalizumab), first…

Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilarto treatrelapsing forms of multiple sclerosis (MS) in EuropeDecision based on evidence from extensive analytical characterization demonstrating similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies. Sandoz is committed to accelerate access to potentially life-changing treatments, while generating savings for healthcare...
Nasdaq GlobeNewswire
26/09/2023

New Campaign, "Ask, Don't Assume," Launched to Challenge Perceptions around…

Aptly titled "Ask, Don't Assume," the campaign aims to raise awareness of the everyday assumptions faced by disabled people and offers practical guidance for allies who are keen to do the right thing. Aptly titled "Ask, Don't Assume," the campaign aims to raise awareness of the everyday assumptions faced by disabled people and offers practical guidance for allies who are keen to do the right thing. Research shows that in the past five years, three-quarters of disabled…
PR Newswire
26/09/2023

Press Release Biocartis Group NV: Biocartis announces H1 2023 Results and…

PRESS RELEASE: INSIDE INFORMATION / REGULATED INFORMATION 26 September 2023, 07:00 CEST BIOCARTIS ANNOUNCES H1 2023RESULTS AND PROVIDES AN UPDATEON THE OPERATIONAL REORGANIZATION AND RECAPITALIZATIONCompany will host a conference call with live webcast presentation today at 14:30 CEST / 13:30 BST (UK) / 08:30 EDT (US) to discuss H1 2023 results Solid performance with 22% growth of oncology cartridge revenue , a 40% gross margin on product sales and a...
Nasdaq GlobeNewswire
26/09/2023

Mithra Financial Results for First-Half 2023

Mithra Financial Results for First-Half 2023 Good progress on strategy to strengthen balance sheet and refocus on innovative R&DRevenues EUR 7.0 million, driven by Estelle® and Myring® salesU.S. Estelle® (Nextstellis®) H1 dispensed cycles surged 80% over H2 2022EU Estelle® (DROVELIS®) revenues hit EUR 1.5 million; launched in new EU and Latam countriesFinancing secured with EUR 20 million private placement in August 2023 and access to EUR 12.5 million...
Nasdaq GlobeNewswire
26/09/2023

Press Release Biocartis Group NV: Agreement regarding recapitalization of…

PRESS RELEASE:INSIDE INFORMATION / REGULATED INFORMATION26 September 2023, 07:00 CEST AGREEMENT REGARDING RECAPITALIZATION OF OPERATING SUBSIDIARIES BY SECURED CREDITORS AND WIND DOWN OF LISTED HOLDING COMPANY The Company's Secured Creditors (being its First Lien Creditors and Bondholders, as defined below) will take ownership of the Biocartis operating subsidiaries through enforcement and inject EUR 40 million of new equity capital to fund the business to EBITDA break-even by the end...
Nasdaq GlobeNewswire
26/09/2023

NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular Atrophy

NMD Pharma initiates Phase II trial of NMD670 in Spinal Muscular AtrophyAarhus, Denmark, 26 September 2023– NMD Pharma A/S, a clinical-stage biotech company developing first-in-class, small molecule ClC-1 inhibitors directly targeting muscle function within neuromuscular disorders, today announces that the first patient has been dosed in a Phase II clinical trial with the ClC-1 inhibitor NMD670 in patients impacted by spinal muscular atrophy (SMA). The patient was dosed under...
Nasdaq GlobeNewswire
26/09/2023

CAR T-cell Therapy for Multiple Myeloma Market to Observe Stunning Growth by…

Key Takeaways from the CAR T-cell Therapy for Multiple Myeloma Market Report Key Takeaways from the CAR T-cell Therapy for Multiple Myeloma Market Report Discover which therapies are expected to grab the major CAR T-cell therapy for multiple myeloma market share @CAR T-cell Therapy for Multiple Myeloma Market Report Multiple Myeloma Overview Multiple myeloma is the second most common hematological malignancy in the world, with a median age of onset of 60 years. This...
PR Newswire
25/09/2023

EssilorLuxottica is building the practice management platform of the future, a…

EssilorLuxottica is building the practice management platform of the future, a digital ecosystem to simplify the lives of ECPs The creation of HELIX represents a major investment in the way eyecare practitioners can leverage modern technologyCharenton-le-Pont, France(September 25, 2023)– EssilorLuxottica is making another important step in the digitization of the eyecare industry with the launch of HELIX, a new division of the Company focused on...
Nasdaq GlobeNewswire
25/09/2023

The Industrial Refrigerants Market Size Is Expected To Grow At A Rate Of More…

Key Drivers for Market Growth Key Drivers for Market Growth Several factors are drivingrefrigerant marketgrowth rate. These include: Learn More On The Refrigerants Market Report –https://www.thebusinessresearchcompany.com/report/refrigerants-global-market-report Fragmented Market Landscape The refrigerants market is characterized by fragmentation, with numerous players operating globally. In 2022, the top ten competitors accounted for 20.40% of the total market share...
PR Newswire
25/09/2023
Altri  Comunicati